Table 4 Clinical and financial outcomes of antibiotic stewardship interventions

Confirmed infections(N)

1009

903

-10.50

(0.6–7.5)

0.80

Amount of antibiotics used(N)

 Third generation cephalosporins

14,569

12,431

-14.67

(1.1–3.7)

< 0.001

 Fluoroquinolones

11,022

10,700

-2.92

(1.3–1.7)

0.031

 Vancomycine

11,001

9920

-9.82

(2.3–6.9)

< 0.001

 Carbapenems

10,980

10,542

-3.98

(0.9–1.4)

0.089

 linezolide

4356

3009

-30.92

(1.8–3.3)

0.043

 Beta-Lactam Beta-Lactamase Inhibitors

7892

5421

-31.31

(1.5–2.3)

0.039

 Polymyxin E

6542

5040

-22.95

(1.2–2.4)

0.01

 Aminoglycosie

7569

5090

-37.89

(0.8–1.6)

0.081

 Metronidazole

12,341

10,070

-18.40

(0.6–1.8)

0.066

Frequency of patients with MRSA isolate (%)

77.20%

(891/1154)

37.14%

(608/1637)

-51.89

(1.3–2.9)

0.03

Frequency of patients with (%) CRE isolate

86.82%

(1002/1154)

54.79%

(897/1637)

-36.89

(1.9-3.3)

0.01

Frequency of patients with KPC isolate

68.45%

790/1549

24.49%

401/1637

-64.22

(2.5–7.5)

< 0.001

Frequency of patients with VRE colonization

55.54%

(641/1154)

18.87%

(309/1154)

-66.62

(3.3–6.4)

0.029

DDD/100 Patient Days

329

201

-38.91

(1.7–2.4)

0.04

Average Monthly Cost of antibiotics prescribed per patient (USD)

137

104

-24.09

(1.3–2.6)

0.03

Total cost of antibiotics (USD)

19,956

15,498

-22.33

(2.2–5.3)

< 0.001

Mean duration of antibiotic use (days) (Mean ± SD)

26.11 ± 11.19

21.90 ± 9.00

-16.12

(1.2–3.4)

0.04

Length of hospital stay (Days)

38.01 ± 17.14

32.00 ± 12.01

-15.81

(0.8–2.1)

0.98

Length of ICU stay (Days)

14.29 ± 4.91

12.11 ± 5.60

-15.25

(0.7–2.1)

0.77

Mortality due to infectious causes

202

198

-1.98

(0.6–2.2)

0.08